Johnson & Johnson News
News on Johnson & Johnson continually updated from thousands of sources around the net.
1 hr ago | Reuters
Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.
Should smoking in public places be banned?
Do undocumented immigrants contribute to the economy?
5 hrs ago | Prince George Citizen
The report from Toronto-based Environmental Defence says the big five all have issues with chemicals that could be harmful to human health, but some are doing better than others.
Johnson & Johnson officials destroyed or misplaced documents related to its vaginal-mesh implants and should be barred from relying on some defenses in planned trials over the devices, patients' lawyers said.
Microsoft Corp. sold $8 billion of bonds in dollars and euros, a record offering from the world's largest software maker that followed Johnson & Johnson by issuing AAA rated corporate securities this week.
But can 2014 keep up with the sort of returns that 2013 delivered? ) , it's a question of how this Dow health care staple can rebound from the patent cliff's withering effects on sales.
Johnson & Johnson and Bayer's drug Xarelto generated $246 million in sales in the third quarter, while sales of Eliquis from Pfizer and Bristol-Myers Squibb were $41 million for the same period.
It's become cliched to talk about Wall Street's hatred for uncertainty. But that's only when it's convenient.
Pomalyst, approved this past February, with the European approval added in August, generated $90 million in the third-quarter.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .
Johnson & Johnson may sell bonds maturing in three, five, 10, 20 and 30 years. CEO Alex Gorsky, in photo above, has helped maintain its top credit ranking despite recent multibillion-dollar settlements over faulty products.
Good roundup from John Lynch in this morning's D-G on the $1.2 billion fine imposed by Circuit Judge Tim Fox in April of 2012 after a jury found Johnson & Johnson liable for Medicaid fraud over the marketing of the anti-psychotic drug Risperdal .
Under a recent settlement, medical insurers may receive $1 billion from Johnson & Johnson for covering the cost of removing recalled hip implants.
However, over the past year, shares of the diversified medical giant have climbed 34% -- outperforming both the market and most of its big-pharma industry peers.